Archer Pharmaceuticals, Inc.
Records under this name other than the patents Archer Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Showing 1 to 9 of 9 · Back to Archer Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,163,162 | Methods and Apparatus for Analyzing a Sample in the Presence of Interferents Formerly held In force · High confidence | In force | High confidence | |
| US 8,236,346 | Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer Lapsed on the fee record Ended Aug 7, 2024 · From the USPTO record | Lapsed on the fee record | Ended Aug 7, 2024 | From the USPTO record |
| US 8,236,347 | Pharmaceutical compositions for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis Formerly held Lapsed on the fee record Ended Aug 7, 2024 · From the USPTO record | Lapsed on the fee record | Ended Aug 7, 2024 | From the USPTO record |
| US 7,589,168 | Inhibition of Angiogenesis by A-Beta Peptides Lapsed on the fee record Ended Sep 15, 2021 · High confidence | Lapsed on the fee record | Ended Sep 15, 2021 | High confidence |
| US 6,011,019 | Vasoactive effects and free radical generation by .beta.-amyloid peptides Term ended Term ended Nov 12, 2016 · From the USPTO record | Term ended | Term ended Nov 12, 2016 | From the USPTO record |
| US 6,787,318 | Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology Lapsed on the fee record Ended Sep 7, 2016 · From the USPTO record | Lapsed on the fee record | Ended Sep 7, 2016 | From the USPTO record |
| US 7,052,852 | CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker in alzheimer's disease Lapsed on the fee record Ended May 30, 2014 · From the USPTO record | Lapsed on the fee record | Ended May 30, 2014 | From the USPTO record |
| US 7,605,149 | Modulation of the phospholipase A2 pathway as a therapeutic Formerly held Lapsed on the fee record Ended Oct 20, 2013 · From the USPTO record | Lapsed on the fee record | Ended Oct 20, 2013 | From the USPTO record |
| US 6,140,309 | Vasoactive effects and free radical generation by .beta.-amyloid peptides Lapsed on the fee record Ended Oct 31, 2012 · From the USPTO record | Lapsed on the fee record | Ended Oct 31, 2012 | From the USPTO record |